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OBJECTIVE: Cell adhesion molecules (intracellular adhe-
sion  molecule-1  (ICAM-1),  vascular  cell  adhesion
molecule-1 (VCAM-1)) and hyaluronic acid, markers
of  inflammation  and  fibrosis  were  monitored  in
hepatitis C patients to determine whether changes in
plasma levels, during antiviral treatment, can predict
long-term response to therapy.
Methods: In 55 patients with chronic hepatitis C virus
(HCV), 33 treated with interferon (IFN) and 22 treated
with  IFN  +  ribavirin,  sera  was  collected  prior  to
treatment, at 3 + 6 months of therapy and 6 months
post-treatment.  Levels  of  ICAM-1,  VCAM-1  and  hya-
luronic  acid  were  correlated  with  alanine  amino-
transferase levels, HCV-RNA-polymerase  chain reac-
tion status and histological fibrosis scoring.
Results: A decrease in ICAM-1 levels at 3 and 6 months
of therapy, compared with pretreatment levels, was
observed in responders to IFN + ribavirin therapy but
this decrease in ICAM-1 levels was not evident follow-
ing cessation of treatment. Hyaluronic acid levels, in
both  treatment  groups,  did  not  differ  significantly
between responders and non-responders. Hyaluronic
acid levels did correlate, significantly, with degree of
fibrosis  whereas  VCAM-1  levels  were  marginally
increased only in patients with moderate (grade III)
fibrosis.
Conclusions:  Monitoring  of  VCAM-1 and hyaluronic
acid, during antiviral therapy, does not differentiate
between responders and non-responders. A decrease
in ICAM-1 levels during IFN + ribavirin treatmment is
associated with response to therapy, and its efficacy
in predicting  long-term response should be further
substantiated.
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Introduction
Leukocyte  adhesion  molecules,  among  them  intra-
cellular  adhesion molecule-1  (ICAM-1)  and  vascular
cell adhesion molecule-1 (VCAM-1), play an integral
role in infiltration, activation and binding of effector
cells to tissues. During  inflammation, activated vas-
cular endothelial cells and other cell  types express
various adhesion molecules that facilitate binding of
circulating leukocytes. Serum concentrations of these
circulating adhesion molecules are thought to reflect
the degree of  this activation. These adhesion mole-
cules  also  play  a  major  role  in  mediating  tissue
damage during allograft rejection.1–4 In the liver of
healthy  controls,  there  is  low  basal  expression  of
ICAM-1 on endothelial cells (liver sinusoidal cells) and
low basal expression of VCAM-1 on both sinusoidal
and  Kupffer  cells.  In  disease  states,  expression  of
adhesion molecules is markedly enhanced and ICAM-
1 can be found also on hepatocytes and on bile duct
epithelium.3 Levels of circulating ICAM-1 and VCAM-1
are increased in patients with hemochromatosis, liver
cirrhosis  and  hepatocellular  carcinoma,  and  have
been shown to be useful in determining the severity
of  liver disease and the degree of fibrosis.1 ICAM-1
expression  on  biliary  epithelium  occurs  in  both
primary  sclerosing  cholangitis  (PSC)  and  primary
biliary cirrhosis (PBC), and while it is less frequently
observed  in  PBC  patients,  in  PSC  its  occurrence
correlates with  advanced stages  of  the disease.2 In
patients  with  chronic  hepatitis  C,  serum  ICAM-1
levels are believed to correlate with degree of active
inflammation, whereas VCAM-1 levels reflect degree
of fibrosis.5
An additional marker of liver fibrosis is hyaluronic
acid,  a  high  molecular  weight  polysaccharide  pro-
duced by mesenchymal cells that is widely distributed
in connective tissues. In the liver, sinusoidal endothe-
lial cells rapidly accumulate and degrade hyaluronic
acid.6 Serum levels of hyaluronic acid are increased in
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chronic hepatitis C virus (HCV), hyaluronic acid levels
were useful  in  detecting unsuspected fibrosis.7,8 In
HCV patients treated with interferon (IFN), response
to therapy has been suggested to be associated with a
decrease  in  ICAM-1  levels;9–12 also,  in  patients  in
whom  post-therapy  biopsies  demonstrated  an
improvement in the degree of fibrosis, a significant
decrease  in  hyaluronic  acid  levels  has  been
observed.13,14
Current  recommendations  regarding  duration  of
therapy in HCV-infected subjects vary, depending on
genotype level of viremia and type of therapy (IFN
monotherapy  versus  IFN  +  ribavirin  combination
therapy), but optimal duration of therapy remains to
be  discerned.15 We  therefore  questioned  whether
monitoring  of  changes  in  ICAM-1,  VCAM-1  and
hyaluronic acid levels during IFN or IFN + ribavirin
therapy can serve in evaluating efficacy of treatment,
thereby  obviating  prolonged  treatment  periods  in
patients who are unlikely to respond.
Patients and methods
Patients
Patient charts were reviewed retrospectively, and the
relevant  clinical  data  were  obtained.  Thirty-three
patients  (Group  1)  were  treated  with  IFN-alpha
monotherapy  (3 ´ 106–6 ´ 106 international  units
(i.u.) thrice weekly), and 22 patients (Group 2) were
treated with combination therapy (3 ´ 106–6 ´ 106
IFN-alpha i.u.  thrice weekly and 600–1200mg  riba-
virin  daily).  Patients  were  randomly  assigned  to
receive either IFN monotherapy or combination (IFN
+ ribavirin) therapy. The mean age was 38.4 ± 13.4
years (Group 1, 40.5 ± 15.0 years; Group 2, 34.6 ±
11.8 years) and the male to female ratio was 1.2 : 1.
Duration of therapy was 6–12 months.
Pre-treatment  liver  biopsies  were  available  in  all
patients and all had chronic non-cirrhotic hepatitis C
related liver disease. Post-treatment liver biopsies were
available in  18  patients who responded to therapy.
Biopsies were grouped based on the degree of fibrosis
according to the modified Knodell scale:16 stage 0, no
fibrosis; stage I + II (mild fibrosis), portal fibrosis with
fibrous portal expansion, or periportal fibrosis with
periportal expansion, or rare portal–portal septae; and
stage  III  (moderate fibrosis),  bridging  fibrosis  with
modular  architecture  distortion.  Patients  with  cir-
rhosis on biopsy were not included.
All  patients  were  Caucasians, with  no  history  of
drug  or  alcohol  abuse  and  no  evidence  for  co-
infection with hepatitis B or HIV.
Definition  of  response  to  therapy: ‘Response  to
therapy was defined as seroconversion to HCV-RNA-
polymerase chain reaction (PCR) negativity’.
Serum analysis
Serum  samples  were  obtained  from  55  anti-HCV+
adult patients who were treated at the Liver Unit of
the  Hadassah  Medical  Center,  Jerusalem  during
1996–1999. Anti-HCV  was  determined  by  the  Cor-
zyme-Enzyme  immunoassay  and  confirmed  by  the
Abbott  HCV-neutralization  EIA  test  (Abbott  Labs.,
North Chicago, IL, USA).
All serum samples were examined for ICAM-1 and
VCAM-1 levels using a radial immunoassay technique
(R+D  System,  Minneapolis,  MN,  USA).  Hyaluronic
acid was determined using an assay based on initial
binding of hyaluronic acid by specific binding protein
(Chigai HA Assay, Chugai Diagnostic; Reaada Medical
Products Inc., CO, USA). Each assay was performed in
duplicate. ICAM-1, VCAM-1 and hyaluronic acid levels
were  correlated  with  biochemical  alanine  amino-
transferase (ALT), virological (HCV-RNA-PCR; Roche)
and  histological  parameters  (Kuodell  score).  Tests
were performed pre-therapy,  at 3  and 6  months of
therapy, and 6 months post-therapy.
Statistical analysis
Results  were evaluated by  one-way analysis of  vari-
ance,  and  correlation  coefficients  were  calculated
using the InStat program. p < 0.05  was considered
statistically significant.
Results
Patients were randomly assigned to two groups: Group
1 were treated with IFN-alpha monotherapy (n = 33),
and Group 2 were treated with combination therapy,
IFN-alpha and ribavirin (n = 22). Past history of blood
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Table 1. ALT levels
Pre-treatment After 3 months therapy After 6 months therapy Follow-up
IFN – responders (n = 10) 115.5 ± 15.1 31.7 ± 6.0 53.9 ± 24.1 39.3 ± 8.0
IFN – non-responders (n = 23) 221.1 ± 34.3 145.0 ± 30.3 144.1 ± 26.3 217.7 ± 32.6
IFN + ribavarin, responders (n = 9) 182.8 ± 19.6 29.9 ± 2.9 26.1 ± 2.5 22.8 ± 3.3
IFN + ribavarin, non-responders (n = 13) 212.3 ± 36.2 128.8 ± 23.4 133.8 ± 19.6 180.5 ± 39.1
Data presented as mean ± SE.transfusion, previous surgery, jaundice, family history
of  chronic  liver  disease  (CLD)  and  hepatocellular
carcinoma were also recorded with similar frequency
in both groups. No significant difference was observed
among groups in levels of hemoglobin, white blood
cells, thrombocytes, prothrombin time, albumin, ALT,
aspartate aminotransferase, alkaline phosphatase, and
other markers for CLD.
ICAM-1, VCAM-1 & hyaluronic acid during HCV therapy
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FIG. 1. (A) ICAM-1 levels (ng/ml) in responders (n = 10) versus non-responders (n = 23) to IFN-alpha monotherapy. (B) ICAM-1
levels (ng/ml) in responders (n = 9) versus non-responders (n = 13) to IFN-alpha + ribavirin combination therapy. (Results
expressed as mean ± SEM.)ALT
Pre-treatment  levels  did  not  differ  between  res-
ponders  and  non-responders  in  both  treatment
groups.  However,  ALT  levels  in  responders  were
significantly lower (p < 0.05) after 3 and 6 months of
therapy  and  at  6  months  following  cessation  of
therapy (Table 1).
ICAM-1
In  patients  receiving  IFN  monotherapy,  differences
between  ICAM-1  levels  in  responders  and  non-
responders  did  not  differ  significantly  at  all  time
points studied (Fig. 1A). In patients receiving IFN +
ribavirin therapy ICAM-1 levels in responders were
significantly  lower  (p <  0.05)  than  levels  in  non-
responders at 3 and 6 months of therapy, while pre-
treatment levels and those 6 months after cessation of
therapy,  albeit  lower  in  responders,  did  not  differ
significantly from those in non-responders (Fig. 1B).
VCAM-1
Levels did not differ significantly between responders
and non-responders at all time points studied (Fig. 2).
Changes in VCAM-1 levels did not correlate with ALT
changes, both in responders and in non-responders.
VCAM-1 levels in patients with moderate fibrosis (F3)
were higher than in patients with no fibrosis (F1) but
differences  were  only  marginally  significant  (p =
0.06).
Hyaluronic acid
In  both  the  monotherapy  and  combination
therapy groups, hyaluronic acid levels did not differ -
significantly  between  responders  and  non-
responders  at  all  time  points  studied.  Changes  in
VCAM-1  levels  did  not  correlate  with  changes  in
hyaluronic  acid levels  both in responders and non-
responders.
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Table 2. Fibrosis scoring versu ALT, ICAM-I, VCAM-I and hyaluronic acid
MT = Monotherapy
CT = Combination therapy
Mild hepatitis
(n = 9; MT = 5; CT = 4)
Moderate to
severe hepatitis
(n = 54; MT = 29; CT = 25)
Active cirrhosis
(n = 10; MT = 6; CT = 4)
ALT (IU) 81.8 ± 10.1 95.9 ± 5.5 67.8 ± 7.5
ICAM-I (ng/ml) 214 ± 84 196 ± 33 200 ± 70
VCAM-I (ng/ml) 872 ± 193 1023 ± 73 1340 ± 144
Hyaluronic acid (ng/ml) 42.3 ± 8.4 62.5 ± 4.5 95.2 ± 8.2
Data presented as mean ± SE.
FIG.  2.  VCAM-1  levels  in  responders  (R)  and  non-responders  (NR)  to  both  IFN  monotherapy  (IFN)  and  IFN  +  ribavarin
combination therapy (IFN + Rib). Results are expressed as percent of pre-treatment levels (pre-treatment levels = 100%).Liver histology
Table  2  summarizes  the  correlation  between  the
degree of fibrosis (F1, no fibrosis; F2, mild fibrosis;
and F3, moderate fibrosis) with levels of ALT, ICAM-1,
VCAM-1  and  hyaluronic  acid  at  the  time  of  liver
biopsy, regardless of response to therapy. Changes in
ALT and ICAM-1 did not correlate with the F score (as
expected). However, VCAM-1 levels  were higher in
the F3 group than in the F1 group, but this difference
was only marginally significant (p = 0.06). Hyaluronic
acid levels were significantly higher in the F3 group as
compared with the F1 and F2 groups (p < 0.01 and p
< 0.05 respectively).
Discussion
Optimal duration of antiviral therapy in chronic HCV
remains  an  unsettled  issue  and  recommendations
vary  depending  on  the  protocols  followed.15,17,18
Markers that may aid in prediction of response, and
thereby  obviate  futile  treatment  in  those  patients
who  are  unlikely  to  respond,  are  thus  of  utmost
importance. Previous studies  have suggested a role
for serum hyaluronic acid determinations in monitor-
ing of response to antiviral therapy. Yamada et al.13
assessed  changes  in  serum  hyaluronic  acid  in  35
patients treated with IFN. In complete responders, a
significant decrease of serum hyaluronic acid levels
was  noted,  in  parallel  with  histological  improve-
ment,  whereas  in  partial  responders  and  non-res-
ponders this decrease in hyaluronic acid levels was
not  observed. A  similar  study  by  Ninomiya  et al.14
substantiated the observation that hyaluronic acid is
a useful marker of liver fibrosis in HCV patients but
emphasized  that  it  cannot  differentiate  sustained
responders from relapsers or non-responders. In our
patients,  although  hyaluronic  acid levels  did  corre-
late  with  degree  of  fibrosis  and  levels  measured
were  indeed  higher  in  non-responders,  during  the
course  of  therapy,  in  each treatment  group,  differ-
ences between responders and non-responders were
not significant. Thus, monitoring of hyaluronic acid
levels at initiation of antiviral therapy and during the
course  of  therapy  cannot  serve  in  predicting
response  but  is,  indeed,  a  useful  parameter  in
assessing liver fibrosis.
VCAM-1  levels  have  also  been  shown  to  reflect
the  degree  of  liver  fibrosis.5,10 Although  in  our
patients  in  whom  biopsies  demonstrated moderate
fibrosis  (F3)  the  levels  were  higher  than  in  HCV
patients  with  no  fibrosis,  differences  were  only
marginally  significant.  Furthermore,  VCAM-1  levels
during the course of therapy did not differ between
responders and non-responders.
ICAM-1 levels, markers of liver inflammation, have
been  shown  to  remain  elevated  in  HCV  patients
who  do  not  respond  to  IFN  therapy,  whereas  in
patients with normal ALT levels following interferon
administration,  ICAM-1  levels  have  significantly
decreased.9–12 In  our  study,  when  analyzing  the
longitudinal  course  of  ICAM-1  levels  within  each
group of  patients, a decrease in  ICAM-1 levels at 3
and  6  months  of  therapy,  compared  with  pre-
treatment  levels,  was  observed  in  responders  to
therapy.  This  decrease  was  most  notable,  and
reached statistical significance, only in the respond-
ers  to  combination  (IFN  +  ribavirin)  therapy. Yet,
even  in  this  group  of  responders,  the  decrease in
ICAM-1 levels was not evident long term; 6 months
following  cessation of  treatment, ICAM-1 levels  did
not differ significantly from pre-treatment levels (Fig.
1). Furthermore, in contrast with the observations of
Baguasco et al.,11 who noted higher basal pretreat-
ment ICAM-1 levels in responders to therapy,  com-
pared with non-responders, in our patients pretreat-
ment  levels  in  responders  and  non-responders  did
not differ significantly.
Thus, although response to IFN + ribavirin antiviral
therapy  is  associated  with  a  transient  decrease  in
ICAM-1  levels,  further  studies  are  needed  to  sub-
stantiate the role of ICAM-1 monitoring in predicting
long-term response. As for the monitoring of VCAM-1
and  hyaluronic  acid  during  antiviral  therapy,  pre-
treatment  levels  and  levels  measured  during  the
course  of  treatment  cannot  serve  in  predicting
response to treatment, nor can their determination
following  cessation  of  therapy  define  responders
from non-responders.
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